U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}
Status:
Investigational
Source:
NCT03020745: Phase 2 Human clinical trial Completed N/A
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Galactosamine is a hexosamine derived from galactose with the molecular formula C6H13NO5. A few amino sugars, including galactosamine, have been shown to kill tumors in the laboratory. It is unlikely to be used in cancer therapy, however. D-galactosamine is a hepatotoxic, or liver-damaging, agent. Researchers studying animal models of liver failure sometimes use D-galactosamine to induce liver damage. Galactosamine is also helpful for researchers studying agents that might protect the liver from damage.
Status:
Investigational
Source:
NCT03020745: Phase 2 Human clinical trial Completed N/A
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)


Conditions:

Galactosamine is a hexosamine derived from galactose with the molecular formula C6H13NO5. A few amino sugars, including galactosamine, have been shown to kill tumors in the laboratory. It is unlikely to be used in cancer therapy, however. D-galactosamine is a hepatotoxic, or liver-damaging, agent. Researchers studying animal models of liver failure sometimes use D-galactosamine to induce liver damage. Galactosamine is also helpful for researchers studying agents that might protect the liver from damage.